FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

Science & Research
5

CJC-1295 + Ipamorelin stack results

London Fischer·6 months ago
Posting my detailed log with before and after observations. I tracked everything meticulously including diet, sleep, exercise, and subjective well-being scores. Happy to answer questions.

Comments (8)

Riley HortonDEMO·8 months ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2
Avery GarciaDEMO·7 months ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

1
Hawk BoothDEMO·7 months ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2
West DonovanDEMO·6 months ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2
Frankie HigginsDEMO·6 months ago

Your meticulous tracking is exactly what this community needs more of. Question about your subjective well-being scores - what scale were you using and did you track at the same time each day? Consistency in subjective measures is surprisingly important.

0
Maple ArnoldDEMO·6 months ago

The sleep improvement with CJC/Ipa is probably the most reliably reported benefit. My deep sleep on Oura went from around 50 minutes to consistently over 90 minutes within the first 2 weeks. That alone justifies the protocol for me.

0
Sage BaileyDEMO·6 months ago

Did you run the CJC-1295 with or without DAC? The no-DAC version gives a more natural pulsatile GH release pattern which some argue is healthier long-term. The DAC version is more convenient with less frequent dosing but creates sustained elevated GH.

0
Beck ArcherDEMO·6 months ago

I have been running this stack for 6 months now with 8-week-on, 4-week-off cycling. The effects seem to maintain well during the off period as long as I keep training and diet consistent. Do you plan to cycle or run continuously?

0

Sign in to comment.